[The Cardiorenal Syndrome].

Area of Science:

• Cardiology
• Nephrology
• Renal Replacement Therapy

Background:

• Chronic heart failure (CHF) presents high morbidity and mortality, especially in elderly patients.
• Cardiorenal syndrome, involving kidney injury in heart failure, significantly worsens patient prognosis.
• Inhibiting the neurohumoral axis and managing hypervolemia are crucial in CHF treatment.

Purpose of the Study:

• To evaluate the role of peritoneal dialysis (PD) as an adjunctive therapy for heart failure patients.
• To assess the benefits of PD in cases of refractory hypervolemia and non-urinary renal failure.
• To explore PD's impact on outcomes in cardiorenal syndrome.

Main Methods:

• Review of current therapeutic options for heart failure with cardiorenal syndrome.
• Analysis of clinical data on patients undergoing PD as part of heart failure management.
• Comparison of outcomes between patients receiving PD and those on other therapies like hemodialysis or VAD implantation.

Main Results:

• Peritoneal dialysis demonstrates biological and clinical advantages in specific heart failure patient cohorts.
• PD effectively manages refractory hypervolemia, a common complication in advanced heart failure.
• The therapy is beneficial for patients with non-urinary renal failure secondary to cardiac conditions.

Conclusions:

• Peritoneal dialysis is a valuable additive therapy for heart failure patients experiencing refractory hypervolemia and renal failure.
• PD offers a viable treatment option, complementing conservative management and other interventions.
• Integrating PD can improve the management and outcomes of complex cardiorenal syndrome.